Compare BLDP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | EVO |
|---|---|---|
| Founded | 1979 | 1993 |
| Country | Canada | Germany |
| Employees | 492 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.3M | 778.3M |
| IPO Year | 2009 | 2007 |
| Metric | BLDP | EVO |
|---|---|---|
| Price | $2.16 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $2.34 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 2.5M | 41.4K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.53 | $1.37 |
| Revenue Next Year | $18.02 | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $1.60 |
| 52 Week High | $6.57 | $4.27 |
| Indicator | BLDP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 28.43 |
| Support Level | $1.98 | N/A |
| Resistance Level | $2.22 | $1.97 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 18.09 | 2.70 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.